Login to Your Account

Novavax Offering Raises $82M for Flu Pandemic, RSV Efforts

By Randy Osborne
Staff Writer

Tuesday, September 24, 2013
With a public offering expected to close later this week that will net the company about $82.6 million for use across its pipeline, Novavax Inc. is moving ahead to finalize cost and timeline details for the next round of trials with its U.S. government-backed quadrivalent seasonal and pandemic influenza vaccines.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription